tbuckley/cabot-search huggingface dataset:
Relationship problems and the DSM:needed improvements and suggested solutions
Authors: RICHARD E. HEYMAN, AMY M. SMITH SLEP, STEVEN R.H. BEACH, MARIANNE Z. WAMBOLDT, NADINE J. KASLOW, DAVID REISS
Journal: World Psychiatry (2009)

The DSM-IV-TR limits mental disorders, by definition, to problems within a person: "a clinically significant behavioral or psychological syndrome or pattern that occurs in an individual and that is associated with present distress (e.g., a painful symptom) or disability (i.e., impairment in one or more important areas of functioning) or with a significantly increased risk of suffering death, pain, disability, or an important loss of freedom" (1).Clinically significant behavioral or psychological syndromes or patterns that occur between or among individuals and that are associated with present distress or disability or with a significant increased risk of suffering death, pain, disability, or an important loss of freedom, receive little attention in the DSM-IV.This article focuses on eleven such syndromes/patterns occurring within families -partner relational problems, parenting problems, parent-child relational problems, partner maltreatment (physical, emotional, and sexual abuse; neglect) and child maltreatment (physical, emotional, and sexual abuse; neglect) -which we will refer to as "relational problems".We briefly review how relational problems are handled in DSM-IV.We sketch the scientific body of research that supports the importance of relational processes to individual's functioning and well-being.We provide several examples of the way criteria could be presented in a clear, structured manner.We present the series of studies that provide evidence of content validity and inter-rater agreement for criteria to determine presence versus absence of relational problems.We discuss the development of screening and diagnostic interviews for relational problems.We present recom-
CUTANEOUS MANIFESTATIONS IN PSYCHOTIC AND PSYCHONEUROTIC INDIVIDUALS
Authors: Eugene F. Bogen
Journal: Annals of Internal Medicine (1937)

Article1 December 1937CUTANEOUS MANIFESTATIONS IN PSYCHOTIC AND PSYCHONEUROTIC INDIVIDUALSEUGENE F. BOGEN, M.D.EUGENE F. BOGEN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-11-6-881 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIt is known that, as a result of their disorder, a small percentage of individuals with nervous or mental abnormalities develop habits which result in skin lesions, or even may become victims of constantly self-inflicted injuries to the skin or mucous membranes. These are cases of true dermatitis factitia. Some of these acts may be the result of a desire for attracting sympathy or attention to the individual, as in one of the cases mentioned recently by Klauder1in which a hysterical woman systematically and secretly used lysol to produce extensive wheals or bands on her arms, which were exhibited...References1. KLAUDER JV: Psychogenic aspects of skin diseases, Jr. Nerv. and Ment. Dis., 1936, lxxxv, 249. CrossrefGoogle Scholar2. ELLER JJ: Neurogenic and psychogenic disorders, Med. Jr. and Rec., 1929, cxxix, 554. Google Scholar3. BONJOUR : Influence of the mind on the skin, Brit. Jr. Dermatol., 1929, xli, 324. CrossrefGoogle Scholar4. JOLTRAIN E: L'emotion, facteur de desequilibre humorar et de dermatoses, Bull. Soc. franç. de dermatol., 1932, xxxix, 1420. Google Scholar5. HORAN M: The psychogenic aspect in dermatology, Practitioner, 1931, cxxvii, 675. Google Scholar6. STOKES JH: The nervous and mental components in cutaneous diseases, Pennsylvania Med. Jr., 1932, xxxv, 229. Google Scholar7. STOKESPILLSBURY JHDM: The effect on the skin of emotional and nervous states, Arch. Dermatol., 1930, xxii, 962. Google Scholar8. CRUTCHFIELD ED: Emotional and psychic factors in skin diseases, Texas State Jr. Med., 1932, xxvii, 707. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: St. Cloud, Minnesota*Received for publication April 10, 1937.Permission granted by Chas. M. Griffith, Medical Director, U. S. Veterans Administration, Washington, D. C. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 December 1937Volume 11, Issue 6Page: 881-888KeywordsHabitsLesionsMucous membranes Issue Published: 1 December 1937 PDF downloadLoading ...
The robotic era of radical prostatectomy: A retrospective analysis of patient characteristics in contemporary robotic and open prostatectomy
Authors: A. Murphy, L. Barlow, M. Mann, K. Badani, M. Benson, J. McKiernan
Journal: Journal of Clinical Oncology (2009)

e16061 Background: As new treatment options become available without being tested in randomized controlled trials, trends in the patient populations receiving these novel therapies often emerge prior to the determination of ideal patient selection factors. In the case of robotic-assisted laparoscopic radical prostatectomy (RALRP), biases in patient selection for this relatively new procedure may influence the evaluation of postoperative outcomes in comparison to open retropubic radical prostatectomy (RRP). This study describes the disease-specific characteristics of patients currently undergoing RALRP and RRP in a contemporary fashion at a single institution. Methods: A total of 1,088 patients who had surgery since the inception of RALRP at our institution (2003–2007) were identified for analysis. The cohort was divided into two groups based on surgical technique (RALRP versus open RRP). Characteristics of the patient pool analyzed included age at surgery, Kattan Nomogram (KN) score, preoperative prostate-specific antigen (PSA), Gleason sum (GS) at biopsy, and pathological tumor stage. Unpaired t-tests with Welch correction and Mann-Whitney tests were used to determine the differences in patient characteristics between the two surgical approaches. Results: The median age was 61. The mean preoperative PSA was 6.2, and GS 2–6, 7, and 8–10 of 48.2%, 40.4%, and 11.4%, respectively. 519 and 569 patients underwent RALRP and RRP, respectively. There was a significant difference between GS (p&lt;0.0001) and tumor stage (p=0.002) between patients undergoing the two approaches. There were trends in favor of younger age, decreased preoperative PSA, and better KN scores in the RALRP group, but these observations lacked statistical significance (age: p=0.06, PSA: p= 0.07, KN: p=0.15). Conclusions: Although there is insufficient evidence to declare an overall difference in patient characteristics between these two surgical approaches in our patient population, trends toward lower-risk patients in the RALRP group suggest a series of patient selection forces for this procedure. These observations have the potential to influence the results obtained in retrospective analyses comparing outcomes between RALRP and open RRP. No significant financial relationships to disclose.
Abstract 16216: Emergency Department Crowding Does Not Predict Door-In-Door-Out Time for Acute Myocardial Infarction Patients Transferred for Acute Coronary Intervention
Authors: Michael J Ward, Olesya Baker, Jeremiah Schuur
Journal: Circulation (2014)

Introduction: Emergency department (ED) crowding and prolonged length of stay (LOS) are associated with lower quality care. Patients with acute myocardial infarction (AMI) should be transferred to percutaneous coronary intervention capable facilities within 45 minutes of arrival. Hypothesis: Increased ED crowding, as measured by ED LOS, is correlated with longer AMI door-in-door-out (DIDO) times at transferring EDs. Methods: We analyzed the Centers for Medicare and Medicaid Services (CMS) quality data. The outcome, DIDO, was CMS measure OP-3b, ED Median Time to Transfer a Patient with AMI for Acute Coronary Intervention . OP-3b data included hospitals with ≥10 AMI cases annually. To measure ED crowding, we used the CMS ED timeliness measures: discharged LOS, admitted LOS, boarding, and waiting time to be seen by a provider. Our primary measure of interest was ED-1: Median ED LOS for Admitted Patients . We analyzed bivariate associations between DIDO and ED timeliness measures. We used linear regression to evaluate the contribution of hospital characteristics from the American Hospital Association survey (academic, trauma, rural, ED volume) to DIDO. Results: Data were available for 405 out of 4,129 hospitals for the CMS DIDO measure (934 had &lt;10 cases). These facilities were primarily non-academic (99%), non-trauma centers (65%), in metro locations (68.6%). Median DIDO was 54 minutes (IQR 42, 68). Increased DIDO time was associated with longer admitted LOS, and boarding times, but not waiting time or discharged LOS. Mean ED admitted LOS was different between hospitals with average DIDO &lt;45 versus those ≥45 minutes (259 vs. 283 minutes; p=0.008). After adjusting for hospital characteristics, longer ED admitted LOS at referring facilities [coefficient, 0.078 (95% CI 0.042, 0.113); p&lt;0.001] was associated with DIDO. A 13 minute increase in ED admitted LOS was associated with a 1 minute increase in DIDO. Among hospital characteristics only rural status was associated with longer DIDO. Conclusions: Among AMI patients presenting to U.S. EDs, we found that ED crowding has a small but operationally insignificant effect on AMI DIDO times. EDs have found ways to facilitate timely transfer of AMI patients despite crowding.
Abstract 2632: Casein kinase II inhibitors regulate cell cycle progression in leukemia
Authors: Chandrika Gowda, Chunhua Song, Mansi Sachdev, Xiaokang Pan, Yali Ding, Kimberley Payne, Sinisa Dovat
Journal: Cancer Research (2014)

Abstract Casein Kinase II (CK2) is an oncogenic kinase that is overexpressed in leukemia. The molecular mechanism by which CK2 exerts its oncogenic function is largely unknown. We have previously demonstrated that CK2 directly phosphorylates the Ikaros tumor suppressor in vivo at multiple, evolutionarily conserved amino acids. CK2-mediated phosphorylation of Ikaros results in reduced DNA binding affinity, loss of pericentromeric localization and impaired Ikaros transcriptional repression. We hypothesize that the pro-oncogenic activity of CK2 in leukemia involves functional inactivation of Ikaros, and that CK2 inhibition will result in restoration of the tumor suppressor function of Ikaros and an anti-leukemia effect. To test this hypothesis, we have tested the effect of specific CK2 inhibitors on Ikaros function as a transcriptional regulator of genes that promote cell cycle progression. Using quantitative Chromatin Immunoprecipitation (qChIP), we have shown that Ikaros binds to the promoters of two genes that are essential for mitosis, ANAPC1 and ANAPC7, in leukemia cell lines and in primary leukemia cells. Increased expression of Ikaros via retroviral transduction was associated with increased binding of Ikaros to the promoters of ANAPC1 and ANAPC7 and their transcriptional repression. Luciferase reporter assay was used to confirm that Ikaros can directly repress transcription of both ANAPC1 and ANAPC7. These data suggest that Ikaros negatively regulates cell cycle progression during mitosis and that Ikaros function as a repressor of ANAPC1 and ANAPC7 is impaired in leukemia. We tested the ability of CK2 inhibition to restore Ikaros repressor activity in leukemia. We evaluated the pre-B acute lymphoblastic leukemia (B-ALL) cell line, Nalm6 treated with a specific CK2 inhibitor, TBB as well as in a murine preclinical xenograft model of B-ALL. CK2 treatment resulted in increased Ikaros binding to promoters of ANAPC1 and ANAPC7, along with transcriptional repression of both genes. This was associated with prolonged survival of B-ALL xenograft mice that were treated with CK2 inhibitors. These data suggest that CK2 inhibitors can regulate cell cycle progression in leukemia cells by restoring the transcriptional repressor function of Ikaros. Our results demonstrate efficacy of CK2 inhibitors as a novel treatment for leukemia. Citation Format: Chandrika Gowda, Chunhua Song, Mansi Sachdev, Xiaokang Pan, Yali Ding, Kimberley Payne, Sinisa Dovat. Casein kinase II inhibitors regulate cell cycle progression in leukemia. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2632. doi:10.1158/1538-7445.AM2014-2632
Book: Oxford Handbook of Clinical Immunology
Authors: C. McSharry
Journal: BMJ (2000)

Gavin Spickett Oxford University Press, £19.95, pp 714 ISBN 019262721X Rating: ![Graphic][1]</img>![Graphic][2]</img>![Graphic][3]</img> As with many of the biosciences, the exciting developments in immunology reported in the literature often seem slightly divorced from current clinical practice. Moreover, most general textbooks of immunology are based on teaching and tend to be visual and referenced. Those that are comprehensive tend to be … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif
Abstract 4420: Results of A Double Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of PS433540 in Human Subjects with Hypertension
Authors: Joel M Neutel, Wilford F Germino, Henry Punzi, Mark McBride, Catherine C Bryson, Rene Belder
Journal: Circulation (2008)

Epidemiologic studies continue to demonstrate extremely disappointing blood pressure (BP) control rates. For this reason, the search for more effective antihypertensive agents continues. PS433540 is the first compound in a novel class of agents called Dual Acting Receptor Antagonists (DARA) which selectively block angiotensin (AT 1 ) and endothelin (ET A ) receptors. In this prospective, randomized, double blind, placebo controlled study, 234 men and women with a mean age of 56.0 years entered a 3– 4 week single blind placebo run-in period. Qualifying stage I or stage II hypertensive patients were randomized in a 1:1:1 ratio to either PS433540 200mg, 500mg or matching placebo for a period of 4 weeks. Ambulatory BP monitoring (ABPM) was performed at the start of the study and was repeated at the end of the treatment period. PS433540 lowered both 24HR Systolic BP (SBP) and Diastolic DBP (DBP) as well as mean office SBP and DBP to a greater extent than placebo, p&lt;0.001. (see Table ) PS433540 was well tolerated with 2 reported serious adverse events in the placebo group and placebo lead-in period. Three patients (all from the placebo group) were discontinued from the study for adverse events. There were no significant laboratory abnormalities. This study demonstrates that PS433540 is an effective and well tolerated new class of antihypertensive agent that may prove to be a very important addition to our armamentarium for the management of hypertension.
420. Adaptation of Baculovirus System for Large-Scale Production of rAAV Vector Serotypes
Authors: Erik Kohlbrenner, George Aslanidi, David R. Knop, Oleg Gorbatyuk, Kevin Nash, Ronald J. Mandel, Nicholas Muzyczka, Barry J. Burns, Richard O. Snyder, Sergei Zolotukhin
Journal: Molecular Therapy (2004)

Scalable production of rAAV vectors is a technically challenging practice. A recently developed baculovirus-based production protocol (Urabe et al), although potentially promising and elegant, proved to be inconsistent and unreliable. Here we report the modification of the original baculovirus system that is amenable to scale-up and suitable for the production of other AAV serotypes similar to conventionally produced vectors. Both Rep and Cap components of the original system have been modified. The Rep52 and Rep78 transcription units of the original BacRep vector were placed onto two separate vectors thereby greatly enhancing the stability of the rep genes for at least 5 continuous passages. In addition, the capsid genes of the BacVP helper were modified by substituting AAV2 VP1 phospholipase A2 (PLA2) domain for the homologous region in the other serotype baculovirus helpers (for example the AAV8 serotype). The resulting chimeric AAV2/8 VP1 reconstituted the wt AAV2 enzymatic PLA2 activity and, consequently, wt AAV8 infectivity. Examples of scale-up production and experiments in vivo will be discussed in detail.
Abstract 13222: Hax1 Overexpression Promotes Sca1+ Cardiac Stem Cell Proliferation and Protects Against Hypoxia-induced Apoptosis
Authors: Wen-Feng Cai, Wei Huang, Sun Wook Kim, Jia-Liang Liang, Rui-Lian Ma, Hideyuki Kondo, Ha Won Kim, Meifeng Xu, Ronald W Millard, Yigang Wang
Journal: Circulation (2014)

Background: HCLS-associated protein X-1 (HAX1) has been reported to regulate cell proliferation and improve cell survival. Here, we investigate whether HAX1 overexpression can promote the capacity for self-renewal and elicit anti-apoptotic effects on sca1+ cardiac stem cells (CSCssca1+). Methods and Results: CSCssca1+ were isolated from mouse hearts and sorted by flow cytometry. The murine HAX1-encoding gene was constructed into a lentivirus (Lenti-HAX1), and then transduced into CSCssca1+. Lentivirus containing non-encoding DNA sequence (Lenti-Null) served as the control. HAX1 expression level increased by 2.3-fold in the Lenti-HAX1 group, without changing CSCssca1+ characteristics (Fig.1A). Flow cytometry cell cycle analysis revealed that the proportion of cells in S-phase was increased by nearly 6 fold in Lenti-HAX1 CSCssca1+ (46%) than in the Lenti-Null group (8%) (Fig. 1B), which was attributed to retinoblastoma protein hyperphosphorylation (Fig. 1C). The number of 5-bromo-2-deoxyuridine (BrdU)-label...
A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study
Authors: KG Blume, KJ Kopecky, JP Henslee-Downey, SJ Forman, PJ Stiff, CF LeMaistre, FR Appelbaum
Journal: Blood (1993)
Thrombectomy After Stroke Improves 90-Day Outcomes
Authors: Amy Thompson
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Our feet set on a new path entirely
Authors: J. T. Hart
Journal: BMJ (1998)

For doctors there are comforting accounts of the birth of the National Health Service, wise professionals defending their own child against meddling politicians.1 But, however you look, BMA leaders, with massive support from general practitioners, stridently opposed participation until three months before the appointed day, and then came grudgingly. An overwhelming majority of patients wanted it, but doctors thought they knew their patients’ best interests—as they always did in those days.
43. Immunological Response Characterization in an Alzheimer's Disease Mouse Model Following HSV Amplicon-Based Aβ Vaccination
Authors: M Griffey, D Wozniak, M Wong, S Rothman, E Bible, Jonathan Cooper, C Vogler, M Sands
Journal: Molecular Therapy (2004)

Batten Disease (Neuronal Ceroid Lipofuscinoses, NCL) refers to a group of inherited neurodegenerative disorders that primarily affect children. Affected children have a disease progression that consists of blindness, seizures, motor and metal decline, and finally premature death. The form with the earliest onset is Infantile Neuronal Ceroid Lipofuscinosis (INCL), and is caused by mutations in the gene that codes for the lysosomal hydrolase palmitoyl protein thioesterase-1 (PPT1). A murine model of INCL, that lacks PPT1 activity, displays many of the same phenotypic characteristics of children with INCL, including: visual deficits, spontaneous seizures, motor deficits, and reduced longevity. To determine if an AAV-mediated gene therapy approach, using an AAV2 vector containing the human PPT1 cDNA (AAV-PPT1), could produce functional improvements in the murine model INCL, we treated newborn PPT1-deficient mice with four intracranial (I.C.) injections of AAV-PPT1 (0.5 ul/site, 1×E10 IU/ml). This group was examined for seizure phenotype, motor function, and longevity of the treated mice.
Northern Ireland's health minister sparks controversy
Authors: Doug Payne
Journal: BMJ (2000)

The first major decision by Northern Ireland's new health minister has generated considerable political controversy. Bairbre de Brun, the Sinn Fein representative for Catholic west Belfast, announced last week that regional maternity services were to be moved from the city's Jubilee Hospital to the Royal Group of hospitals site in west Belfast.

Neonatal services will be transferred first, and the rest of the unit should follow within 90 days. A new maternity hospital will be built at the Royal site, next …
121. Specific Targeting of Adenoviral Vectors Using the Reovirus Attachment Protein
Authors: Frederik H. E. Schagen, Jan E. Carette, Terence S. Dermody, Winald R. Gerritsen, Victor W. van Beusechem
Journal: Molecular Therapy (2004)

Many primary tumors do not express the adenovirus receptor CAR, which limits the applicability of adenoviral vectors (AdV) for cancer gene therapy. The high affinity of reovirus for cancer cells, in particular malignant gliomas, and the structural homology displayed by reovirus attachment protein σ1 and adenovirus fiber suggests that σ1 could be used to target AdV to cancer cells. To investigate this possibility, we generated a fiber/σ1 fusion protein by exchanging the σ1 capsid anchoring-domain for its analog in fiber, the tail domain. The resulting fusion protein efficiently formed trimers, as shown by immunoblotting, and complemented propagation of the fiberless LacZ-expressing AdV, Ad5.βgal.ΔF (Von Seggern et al. J. Virol. 1999, 73: 1601), resulting in infectious virus. Gene transfer by Ad5.βgal.ΔF complemented with the fiber/σ1 fusion protein was inhibited by neutralizing anti-σ1 antibody but not by neutralizing anti-fiber antibody, confirming that σ1 mediated specific cell binding, most probably by interactions with the reovirus receptor, JAM1. Moreover, fiber/σ1-complemented Ad5.βgal.ΔF transduced a small panel of primary human malignant gliomas about 10-fold more efficiently than did AdV containing native fiber.